VK2735
VK2735 (dual GLP-1 / GIP agonist)
Viking Therapeutics' dual GLP-1 and GIP agonist in Phase 3 as an injection, with an oral version showing rapid early weight loss.
Overview
VK2735 is Viking Therapeutics' dual GLP-1 and GIP receptor agonist, in the same mechanistic class as tirzepatide. The injectable form advanced to Phase 3 (VANQUISH) after Phase 2 showed roughly 14.7% weight loss in about 13 weeks, and an oral form showed around 12.2% at 13 weeks, among the fastest early responses of any oral agent. It is investigational. Update, September 2026: both Phase 3 VANQUISH trials of the weekly injection are fully enrolled (VANQUISH-1, about 4,650 adults, November 2025; VANQUISH-2 in type 2 diabetes, March 2026), each running 78 weeks.
Mechanism of action
Agonizes both the GLP-1 and GIP receptors to enhance insulin secretion, reduce appetite, and slow gastric emptying.
Key studies & citations
- Human2026
Weekly subcutaneous VK2735, a GIP/GLP-1 receptor dual agonist, for weight management: phase 2, randomized, 13-week VENTURE study
Weight fell 9.1% to 14.7% across doses at 13 weeks versus 1.7% with placebo; 93% lost at least 5%.
Obesity - Human2025
Viking Therapeutics announces completion of enrollment in Phase 3 VANQUISH-1 trial of VK2735
November 19, 2025: about 4,650 adults enrolled in the 78-week Phase 3 VANQUISH-1 trial of weekly subcutaneous VK2735.
Viking Therapeutics press release - Human2026
Viking Therapeutics presents data from its 13-week Phase 2 VENTURE-Oral Dosing trial of VK2735 at ECO 2026
Oral VK2735 produced dose-dependent weight loss up to 12.2% (26.6 lb) at 13 weeks.
Viking Therapeutics press release
Frequently asked questions
How is VK2735 different from tirzepatide?
Both are dual GLP-1/GIP agonists. VK2735 is investigational and is being developed in both injectable and oral forms, while tirzepatide is approved and injected.